Organon & Co. (OGN) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
Organon & Co. (OGN) Profile & Business Summary
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Key Information
| Ticker | OGN |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.organon.com |
Market Trend Overview for OGN
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-03-25 (ET)
As of 2026-03-25, OGN is moving sideways without a clear direction. Over the longer term, the trend remains bearish.
OGN last closed at 6.10. The price is about 0.3 ATR below its recent average price (6.21), and the market is currently in a sideways market without a clear direction. Price at 6.10 is moving between minor support near 5.76 and minor resistance near 6.53. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still negative, but short-term signals are not yet confirming it.
There is no clear risk level acting as a key boundary right now.
On 2026-02-02, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-03-19] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not issue an actionable directional forecast. Predictability is 43%, agreement is 93%, and reversal risk is 26%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 3.4% below the recent estimated cost basis of 6.32, so the recent structure is still leaning under pressure. Price is in the lower half of the main cost band (6.04 to 6.24), so price support and pullback behavior matter more than immediate upside follow-through. The lower down support area sits around 5.86 to 5.88. It looks more like a first buffer than a major floor. Roughly 74% of recent positioning remains under water, so rebound attempts can still run into supply from trapped holders. From a trading point of view, the main question is whether pullbacks remain controlled before price falls back into the lower support zone.
Short Interest & Covering Risk for OGN
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is within its typical range, with no clear imbalance between buyers and sellers. (Historical percentile: 50%)
Structure Analysis
OGN Short positioning looks normal. Current days to cover is 3.7 trading days, meaning short positions would unwind somewhat slower than average. Short covering is likely to have a normal impact on price moves. Price is already trending lower (20D return -18.8%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Average trading volume is weakening, indicating contracting liquidity. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-02-27 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.